Michael J. Fox Foundation

Accure Therapeutics S.L. is a pharmaceutical company based in Barcelona, Spain, focused on the development, production, and marketing of drugs aimed at treating central nervous system (CNS) diseases. As a clinical-stage research and development entity, Accure Therapeutics specializes in creating disease-modifying therapies for both severe orphan and non-orphan CNS disorders. The company is committed to accelerating the transition to effective treatments for disabling brain conditions, thereby enabling healthcare professionals to better address the complexities of CNS-related illnesses.

Endlyz Therapeutics develops disease-modifying therapeutics intended to restore endo-lysosomal function and abrogate neurodegeneration in Parkinson’s disease and other dementias, with a focus on technologies that address early disease progression.

Kazia Therapeutics is an Australian biotechnology company focused on oncology drug development. It specializes in creating brain-penetrant cancer therapies, with its lead candidate being paxalisib for glioblastoma treatment. Additionally, it develops Cantrixil for ovarian cancer and collaborates globally with renowned institutions to advance its research.

Founded in 2007 by scientists from Washington University School of Medicine and LifeTech Research, C2N Diagnostics specializes in protein diagnostic testing services for neurological disorders. Utilizing mass spectrometry-based analysis, the company aims to provide accurate and sensitive diagnostics for conditions like Alzheimer's disease.

Grifols is a global healthcare company specializing in the research, development, production, and commercialization of plasma-derived proteins. These therapies treat chronic and acute conditions such as immunological deficiencies and hemophilia.

NurrOn Pharmaceuticals is an innovative pharmaceutical company focused on developing disease-modifying therapies for Parkinson's disease and other Nurr1-related disorders. The company is dedicated to creating novel targeted therapeutics aimed at alleviating symptoms of these conditions by protecting dopaminergic neurons, which are crucial for motor control and function. Through its research and development efforts, NurrOn Pharmaceuticals seeks to improve clinical outcomes for patients suffering from Parkinson's disease, addressing a significant unmet medical need in the treatment of this incurable disorder.

CND Life Sciences develops an evidence-based tool for confirming synucleinopathy diagnoses. Its Syn-One Test detects abnormal alpha-synuclein in cutaneous nerve fibers, aiding in diagnosing Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, and pure autonomic failure.

Bexion Pharmaceuticals is a biotechnology company developing biologic cancer therapies with a novel mechanism of action aimed at targeting tumor cells and the tumor vasculature. Founded in 2006 and based in Covington, Kentucky, the company concentrates on solid tumors and related indications, leveraging sphingolipid metabolism to promote tumor cell death. Its approach includes targeting phosphatidylserine patches common to tumor cells and neovasculature, which is thought to trigger apoptosis via the acid sphingomyelin-ceramide pathway, potentially modulating cell proliferation and immune responses.

Founded in 2018 by industry veterans in neuroscience drug discovery, NRG Therapeutics is a biotechnology company dedicated to developing therapeutic approaches that restore mitochondrial function. Their primary focus is slowing or halting the progression of neurodegenerative diseases like Parkinson's and Alzheimer's through innovative drug discovery.

SandboxAQ specializes in developing advanced artificial intelligence and quantum technology products. The company integrates expertise from diverse fields to create Large Quantitative Models and AI sensing applications, focusing on practical solutions for industries such as financial services, healthcare, and telecommunications.

Selonterra, Inc. is a biopharmaceutical company focused on developing innovative therapeutics for Alzheimer's disease and Parkinson's disease. Founded in 2017 and headquartered in San Mateo, California, the company aims to address the unmet medical needs of patients suffering from these neurodegenerative disorders. Selonterra specializes in harnessing human genetics and gene regulatory networks to create therapies that target the function and expression of specific proteins involved in these diseases. Through its efforts, the company seeks to provide healthcare professionals with potentially disease-modifying treatments that could improve patient outcomes.

Herantis Pharma is a biotech company focused on addressing unmet clinical needs, particularly in the field of neurodegenerative diseases. The company's primary development program centers on HER-096, a peptidomimetic molecule designed to mimic the biological activity of the neuroprotective CDNF protein. By targeting Parkinson's disease, Herantis Pharma aims to develop disease-modifying therapies that could significantly improve patient outcomes.

MISSION Therapeutics is a biotechnology company specializing in developing drugs that target the cellular process of deubiquitylation for the treatment of cancer and other diseases. Their focus is on developing small molecule drugs that selectively inhibit specific deubiquitylating enzymes (DUBs), which play crucial roles in regulating protein degradation and cellular processes. These drugs aim to intervene in disease mechanisms where DUB dysregulation is implicated, offering potential therapeutic benefits.

Kannalife, a subsidiary of Neuropathix, Inc (OTCQB: NPTX), is a biopharmaceutical company focused on discovering, developing, and commercializing a product platform of novel molecules from our proprietary next-generation cannabinoid therapeutics as potent, non-opioid alternatives to treat patients with a variety of unmet medical needs.

Alchemab Therapeutics Ltd is a biotechnology company based in London, United Kingdom, focusing on the discovery and development of novel therapeutics aimed at patients with hard-to-treat diseases. Established in 2019 by Uri Laserson and Jane Osbourn, the company utilizes a transformative approach to identify drug targets and build a pipeline of antibody therapeutics. Alchemab's strategy involves harnessing naturally protective antibodies through an unbiased and function-first methodology that employs complementary processes and technologies. This innovative approach aims to provide treatments for various challenging conditions, including hard-to-treat cancers, neurodegenerative disorders, and infectious diseases.

Lucy Therapeutics is a biotechnology company focused on developing innovative treatments for neurological diseases by targeting mitochondrial dysfunction. The company employs a unique approach to drug discovery, concentrating on drugging targets linked to the early stages of disease pathogenesis. This methodology not only addresses specific neurological conditions but also has the potential to extend treatment options for other related disorders, such as Parkinson's Disease and Alzheimer's Disease. Additionally, Lucy Therapeutics is dedicated to creating proprietary small molecule therapies and diagnostic biomarkers aimed at enhancing the understanding of the central nervous system. By leveraging advanced genetic technologies, the company aims to provide insights into personalized medicine, thereby improving patient outcomes and enabling more precise healthcare interventions.

NeuroRestore is a research and innovation institution that develops and implements medical remedies to restore neurological functions.

Vesper Bio is a clinical-stage biotechnology company that makes an observation that may enable the development of a cure/treatment against a devastating or fatal disorder.

IRLAB Therapeutics AB is a Swedish research and development company focused on creating innovative drug treatments for neurological disorders, particularly Parkinson's disease. The company has developed several clinical candidates, including Mesdopetam, a dopamine D3 receptor antagonist that has completed Phase IIa trials for dyskinesia, and IRL752, which has also progressed through Phase IIa trials for postural dysfunction. In addition to these, IRLAB is advancing other research initiatives aimed at addressing neurodegenerative conditions and the effects of aging. These include programs designed to develop alternatives to levodopa, a common Parkinson's treatment, and additional compounds targeting various dysfunctions associated with Parkinson's disease. Based in Gothenburg, Sweden, IRLAB is committed to enhancing the quality of life for patients suffering from neurological and psychiatric illnesses through its innovative therapeutic approaches.

Octave is a clinical platform developer focused on transforming the care landscape for multiple sclerosis and other neurodegenerative diseases. The company creates a platform that generates, analyzes, and integrates data to improve patient outcomes and reduce overall healthcare costs. By optimizing medication usage and healthcare services, Octave aims to enhance the efficiency of the pharmaceutical industry throughout the entire lifecycle of drug development, which includes discovery, clinical trials, and post-marketing phases. Their approach utilizes real-world evidence to inform decision-making, ultimately striving to set a new standard in multiple sclerosis care.

Nine Square Therapeutics is engaged in the development of small-molecule therapeutics aimed at treating degenerative movement disorders, including Parkinson's disease and amyotrophic lateral sclerosis (ALS), as well as non-degenerative conditions such as essential tremor and dyskinesias. Founded in 2020 and based in New York, the company employs an innovative approach that combines computational chemistry, biophysics, and computational biology with machine-learning-enabled cell profiling platforms. This methodology enhances the processes of target identification, chemical optimization, and patient stratification, enabling healthcare professionals to more effectively address the challenges posed by these movement disorders.

Cantabio Pharmaceuticals, Inc. is a preclinical stage biotechnology company based in Palo Alto, California, focused on the research, development, and commercialization of innovative therapies for neurodegenerative diseases, particularly Parkinson’s disease and Alzheimer’s disease. The company's lead programs include CB101, a small molecule pharmacological chaperone targeting the DJ-1 protein for Parkinson’s disease, and CB201, an engineered DJ-1 protein designed to penetrate the central nervous system. Additionally, Cantabio is developing CB301, a small molecule targeting Tau protein for Alzheimer's disease, and CB401, which targets amyloid-beta for the same condition. The company also collaborates with the Luxembourg Institute of Health to explore therapeutic strategies targeting the DJ-1 protein for immune-associated diseases. Founded in 2009, Cantabio is committed to advancing novel therapeutic options and leveraging the intellectual property generated from its research efforts.

NysnoBio is a biotechnology company focused on developing innovative therapies for serious medical conditions, with a particular emphasis on Parkinson's disease. The company was the first to identify the Parkin gene's association with Parkinson's disease and to demonstrate that Parkin functions as an E3 ubiquitin ligase. NysnoBio has pioneered several key advancements, including publishing the crystal structure of essential parts of enzymology and utilizing adeno-associated virus (AAV) in gene therapy. Their approach involves developing small molecule activators for the Parkin protein and employing gene therapy to preserve dopamine neurons, aiming to provide effective treatments for Parkinson's disease patients.

Neuronity Therapeutics, established in 2022 and based in Mansfield, USA, is a biotechnology company specializing in the development of gene therapy treatments for neurological disorders. Its primary focus is on combating age-related neurodegeneration, such as Parkinson's disease, by promoting the body's natural immune response and restoring its immunity within the central nervous system.

Ventus Therapeutics is a biopharmaceutical company focused on discovering and developing innovative small molecule medicines that target the innate immune system. The company employs a structural immunology platform that provides deep insights into molecular structures and mechanisms, enabling precise targeting of the innate immune system. Ventus combines advanced protein engineering capabilities with cutting-edge rational and structure-based drug design tools to create therapeutics aimed at treating autoimmune diseases, inflammatory conditions, and cancer. The company is actively building a diverse pipeline of drug programs that address significant targets within the innate immune system, with the goal of advancing treatments for both acute and chronic inflammatory and immune-related diseases.

Icometrix specializes in enhancing patient care through AI-driven imaging analysis. Founded in 2011 as a spin-off from Belgian universities, it offers standardized measurements on brain MRI scans for neurological disorder patients. Its flagship product, MSmetrix, detects lesions and measures volumes, with EU market approval and pending FDA clearance. Icometrix also supports clinical trials and research studies, processing large batches of imaging data.

Lys Therapeutics is a biotechnology company focused on developing therapies for patients with neurovascular and neurodegenerative disorders. The company is notable for its lead drug, Glunozumab, a monoclonal antibody that employs a novel mechanism of action. This drug hyperactivates both vascular and neuronal NMDA receptors, leading to off-target toxicity that can disrupt the blood-brain and blood-spinal cord barriers, resulting in neuronal excitotoxicity associated with conditions such as stroke and multiple sclerosis. Lys Therapeutics aims to address neuroinflammation and its effects on neurodegeneration through innovative biotherapies.

Olatec Therapeutics is a biopharmaceutical company focused on developing safe, oral therapeutics that act as NLRP3 antagonists to treat and prevent a range of acute and chronic inflammatory diseases. These conditions, which are often mediated by Interleukin-1, include arthritis, heart failure, asthma, Alzheimer’s disease, multiple sclerosis, type-2 diabetes, melanoma, and breast cancers. The company's lead compound, dapansutrile, selectively targets the NLRP3 inflammasome, inhibiting the production of pro-inflammatory cytokines IL-1B and IL-18. With a team of experienced professionals and thought leaders in inflammation and immunology, Olatec aims to advance its proprietary pipeline of NLRP3 inhibitors to address significant unmet medical needs. The company operates in the United States and Europe, with offices in New York and the Netherlands.

Selonterra, Inc. is a biopharmaceutical company focused on developing innovative therapeutics for Alzheimer's disease and Parkinson's disease. Founded in 2017 and headquartered in San Mateo, California, the company aims to address the unmet medical needs of patients suffering from these neurodegenerative disorders. Selonterra specializes in harnessing human genetics and gene regulatory networks to create therapies that target the function and expression of specific proteins involved in these diseases. Through its efforts, the company seeks to provide healthcare professionals with potentially disease-modifying treatments that could improve patient outcomes.

Founded in 2018 by industry veterans in neuroscience drug discovery, NRG Therapeutics is a biotechnology company dedicated to developing therapeutic approaches that restore mitochondrial function. Their primary focus is slowing or halting the progression of neurodegenerative diseases like Parkinson's and Alzheimer's through innovative drug discovery.

Newel Health specializes in developing and commercializing digital medicine and digital therapeutic solutions, partnering with pharmaceutical companies and other health stakeholders. Leveraging data and technology, they focus on human-centered design to improve healthcare outcomes.

Esya is a biotechnology company focused on advancing the diagnosis and treatment of neurodegenerative diseases, such as dementia. The company has developed a nanotechnology device that performs a straightforward blood test or skin biopsy to measure and monitor disease progression. This innovative approach not only aids in diagnosing neurocognitive impairments but also supports pharmaceutical companies in drug development by quantifying patient responses to treatment. By facilitating the pre-assessment of patient cohorts, Esya enables scientists to create personalized medicine tailored to individual needs, enhancing the overall effectiveness of therapeutic interventions.

Amydis is a privately-held pharmaceutical company dedicated to developing innovative diagnostic tools for detecting diseases linked to amyloid protein deposits. Its core technology involves novel compounds that fluoresce upon binding to amyloid proteins, enabling non-invasive diagnosis. Amydis' primary focus is on early-stage Alzheimer's disease detection, with other potential applications including Parkinson's disease, Creutzfeldt-Jakob disease, and various forms of amyloidosis. The company aims to provide faster, more accessible, and affordable diagnostic solutions compared to existing methods, contributing to better healthcare decisions for patients and their families.

Muna Therapeutics is a biopharmaceutical company dedicated to discovering and developing therapies aimed at slowing or halting devastating neurodegenerative diseases such as Parkinson's, Alzheimer's, Frontotemporal Dementia, and Multiple Sclerosis.

Seelos Therapeutics is a clinical-stage biopharmaceutical company based in New York, founded in 2016. It specializes in developing novel therapeutics to address unmet medical needs, particularly focusing on central nervous system (CNS) disorders and other rare conditions. The company's lead programs include SLS-002, an intranasal racemic ketamine for treating acute suicidal ideation and behavior in patients with major depressive disorder and post-traumatic stress disorder; SLS-005, a protein stabilizer for Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for Parkinson's disease. Additionally, Seelos Therapeutics has several preclinical programs targeting various conditions such as Parkinson's disease, chronic inflammation in asthma, narcolepsy, and post-operative pain management.

Koneksa Health Inc. is a healthcare data analytics company that specializes in designing and developing software solutions for pharmaceutical and biotech firms. The company’s flagship product, Koneksa Compare, facilitates the collection, monitoring, and analysis of patient-generated data to support clinical studies and regulatory claims. By integrating emerging technologies such as bio-sensors, activity trackers, and mobile-based questionnaires, Koneksa enhances the accuracy and breadth of data that researchers can analyze, thereby minimizing subjective biases in clinical endpoints. Additionally, the platform provides a dashboard that offers electronic clinical outcome assessments and reminders for study participants. Established in 2013 and headquartered in New York, Koneksa also maintains a presence in London, United Kingdom, and is recognized for its contributions to improving the efficiency of drug development through innovative data analysis.

ZyVersa Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Weston, Florida, focused on developing innovative therapeutics for patients suffering from inflammatory and renal diseases with significant unmet medical needs. The company’s clinical pipeline features VAR 200, a cholesterol efflux mediator currently ready for phase 2a trials, aimed at treating focal segmental glomerulosclerosis, a rare kidney disease. Additionally, ZyVersa is advancing a novel inflammasome inhibitor, IC 100, which has the potential to address multiple inflammatory conditions. Established in 2014 and originally known as Variant Pharmaceuticals, ZyVersa Therapeutics leverages proprietary technologies to create first-in-class drugs tailored to the needs of underserved patient populations.

EpicentRx Inc., a clinical-stage biotechnology company based in La Jolla, California, specializes in developing immunotherapy solutions for cancer treatment. The company's portfolio includes RRx-001, a suite of immunotherapeutic compounds designed to convert treatment-resistant tumors into sensitive ones by normalizing the tumor microenvironment, activating the innate immune system, and sensitizing solid tumors to standard therapies. Additionally, EpicentRx offers AV-255, a genetically altered adenovirus that infects and kills cancer cells. The company, founded in 2002 and formerly known as RadioRx, Inc., is led by actively practicing oncologists who are deeply motivated by the plight of cancer patients, driving their efforts to personalize immunotherapies for individuals with limited treatment options or undruggable mutations.

Koneksa Health Inc. is a healthcare data analytics company that specializes in designing and developing software solutions for pharmaceutical and biotech firms. The company’s flagship product, Koneksa Compare, facilitates the collection, monitoring, and analysis of patient-generated data to support clinical studies and regulatory claims. By integrating emerging technologies such as bio-sensors, activity trackers, and mobile-based questionnaires, Koneksa enhances the accuracy and breadth of data that researchers can analyze, thereby minimizing subjective biases in clinical endpoints. Additionally, the platform provides a dashboard that offers electronic clinical outcome assessments and reminders for study participants. Established in 2013 and headquartered in New York, Koneksa also maintains a presence in London, United Kingdom, and is recognized for its contributions to improving the efficiency of drug development through innovative data analysis.

AlzProtect is a biopharmaceutical company dedicated to developing drug candidates for the treatment of neurodegenerative diseases, particularly Alzheimer's disease and orphan tauopathies like Progressive Supranuclear Palsy. The company focuses on research related to tauopathies, where neuronal degeneration arises from the abnormal aggregation of hyperphosphorylated Tau proteins and associated inflammation. By advancing its drug candidates from discovery through clinical trials, AlzProtect aims to provide innovative therapeutic solutions for these challenging conditions, addressing significant unmet medical needs in the field of neurodegeneration.

Modality.AI, Inc. is a healthcare technology company based in San Francisco, California, founded in 2018. It specializes in AI-powered solutions that enhance the efficiency of clinical trials for neurological and mental health therapies. The company's platform utilizes conversational AI to engage patients through naturalistic spoken interaction, allowing for continuous health assessments anytime and anywhere. By analyzing multimodal data, including audio-visual biomarkers, Modality.AI provides objective measures that correlate with clinical outcomes. This innovative approach enables pharmaceutical companies to conduct self-driven assessments and improve the monitoring of health conditions, ultimately facilitating more effective clinical trials.

Asceneuron is a biotechnology company dedicated to discovering and developing therapeutics for neurodegenerative disorders with high unmet medical needs. It focuses on orphan tauopathies, Alzheimer's disease, and Parkinson's disease.

AcureX Therapeutics is a biotechnology company dedicated to halting neurodegenerative diseases, initially focusing on Parkinson’s Disease. It specializes in identifying and addressing defects in mitophagy, the process by which cells dispose of dysfunctional mitochondria.

Lucy Therapeutics is a biotechnology company focused on developing innovative treatments for neurological diseases by targeting mitochondrial dysfunction. The company employs a unique approach to drug discovery, concentrating on drugging targets linked to the early stages of disease pathogenesis. This methodology not only addresses specific neurological conditions but also has the potential to extend treatment options for other related disorders, such as Parkinson's Disease and Alzheimer's Disease. Additionally, Lucy Therapeutics is dedicated to creating proprietary small molecule therapies and diagnostic biomarkers aimed at enhancing the understanding of the central nervous system. By leveraging advanced genetic technologies, the company aims to provide insights into personalized medicine, thereby improving patient outcomes and enabling more precise healthcare interventions.

ND BioSciences is a biotechnology company that was founded with the mission of developing and providing innovative technologies, solutions, tools, assays, and services to accelerate the development of early diagnostics and therapies for neurodegenerative diseases.

Arkuda Therapeutics, Inc. is a biotechnology company founded in 2018 and based in Cambridge, Massachusetts, focused on developing innovative treatments for patients with neurological diseases. The company utilizes new insights into progranulin and lysosomal biology to create therapies that aim to correct progranulin deficiency and address lysosomal dysfunction, particularly in genetically-defined frontotemporal dementia associated with mutations in the GRN gene. By targeting these underlying biological mechanisms, Arkuda's lead compounds are designed to improve cellular health in the brain, potentially delaying the progression of neurodegenerative diseases and the onset of their symptoms.

MISSION Therapeutics is a biotechnology company specializing in developing drugs that target the cellular process of deubiquitylation for the treatment of cancer and other diseases. Their focus is on developing small molecule drugs that selectively inhibit specific deubiquitylating enzymes (DUBs), which play crucial roles in regulating protein degradation and cellular processes. These drugs aim to intervene in disease mechanisms where DUB dysregulation is implicated, offering potential therapeutic benefits.

Sinopia Biosciences is a company focused on revolutionizing drug discovery and disease research through a data-driven platform. By integrating high-throughput screening, multi-omics data, artificial intelligence, and network analysis, Sinopia aims to identify and advance novel therapeutics more effectively than traditional target-based approaches. Recognizing the complexities and unclear etiologies of many diseases, the company emphasizes phenotypic screening, which has demonstrated higher productivity in discovering first-in-class medications. This innovative methodology enables researchers to explore disease mechanisms and potential treatments in greater depth, ultimately facilitating the development of new and effective therapies.

Founded in 2018 by industry veterans in neuroscience drug discovery, NRG Therapeutics is a biotechnology company dedicated to developing therapeutic approaches that restore mitochondrial function. Their primary focus is slowing or halting the progression of neurodegenerative diseases like Parkinson's and Alzheimer's through innovative drug discovery.

Wealthsimple Financial Inc. is a Toronto-based company that specializes in providing digital investment advisory services across Canada and operates additional offices in Brooklyn, New York, and London, United Kingdom. Founded in 2014, Wealthsimple offers a range of financial tools designed to help investors grow and manage their money. The company builds diversified portfolios of exchange-traded funds (ETFs) on behalf of its clients, offering accessible and affordable investment management without the high fees and account minimums typical of traditional firms. Wealthsimple also provides on-demand financial planning solutions and a hybrid savings and spending product known as Wealthsimple Cash. As of September 2020, Wealthsimple operates as a subsidiary of Purpose Advisor Solutions Inc.

MapLight Therapeutics is focused on discovering and developing innovative therapies for brain disorders. The company utilizes a unique platform that integrates single-cell transcriptomics with optogenetics, enabling the identification of novel drug targets. By leveraging these advanced technologies, MapLight aims to create effective treatments tailored to address complex neurological conditions. Founded in 2018 and based in San Francisco, California, the company is committed to advancing the understanding and treatment of brain disorders through its cutting-edge research and development efforts.

Caraway Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, that focuses on developing innovative treatments for neurodegenerative diseases by modulating mitophagy and autophagy. The company aims to address the degradation of toxic cellular components, which is a key factor in various neurodegenerative conditions, including Parkinson's disease and amyotrophic lateral sclerosis. By leveraging an understanding of critical neural pathways, Caraway Therapeutics seeks to discover and develop novel small molecules that can restore cellular balance and improve lysosomal function. Founded in 2018 and initially known as Rheostat Therapeutics, Inc., the company rebranded in 2019 to reflect its commitment to finding effective therapies for patients affected by these debilitating diseases.

Amydis is a privately-held pharmaceutical company dedicated to developing innovative diagnostic tools for detecting diseases linked to amyloid protein deposits. Its core technology involves novel compounds that fluoresce upon binding to amyloid proteins, enabling non-invasive diagnosis. Amydis' primary focus is on early-stage Alzheimer's disease detection, with other potential applications including Parkinson's disease, Creutzfeldt-Jakob disease, and various forms of amyloidosis. The company aims to provide faster, more accessible, and affordable diagnostic solutions compared to existing methods, contributing to better healthcare decisions for patients and their families.

Med-Life Discoveries is a biopharmaceutical company based in Saskatoon, Canada. It specializes in developing synthetic plasmalogens and plasmalogen precursors for treating diseases like Alzheimer's and Parkinson's. The company aims to address metabolic abnormalities that precede disease development.

H. Lundbeck is a Denmark-based global pharmaceutical company dedicated to improving the quality of life for individuals with psychiatric and neurological disorders. The company specializes in the research, development, production, marketing, and sale of pharmaceuticals targeting various conditions such as depression, schizophrenia, Parkinson's disease, and Alzheimer's disease. Lundbeck's product portfolio includes medications like Abilify Maintena, Rexulti, Brintellix, Northera, Sabril, and Vyepti, addressing issues ranging from psychosis to migraine prevention. With a workforce of approximately 5,300 employees across 55 countries, the company operates research facilities in Denmark and China, as well as production sites in multiple countries, including China, Denmark, France, and Italy. By focusing heavily on research and development, Lundbeck aims to meet the ongoing demand for innovative therapeutics, as there remains a significant unmet need in the treatment of these serious disorders, which affect millions globally.

Founded in 2013, Olaris is dedicated to transforming disease diagnosis and treatment. Utilizing its CEREBRO platform, which integrates metabolomics and machine learning, the company discovers and develops precision diagnostics under its myOLARIS™ brand.

Sinopia Biosciences is a company focused on revolutionizing drug discovery and disease research through a data-driven platform. By integrating high-throughput screening, multi-omics data, artificial intelligence, and network analysis, Sinopia aims to identify and advance novel therapeutics more effectively than traditional target-based approaches. Recognizing the complexities and unclear etiologies of many diseases, the company emphasizes phenotypic screening, which has demonstrated higher productivity in discovering first-in-class medications. This innovative methodology enables researchers to explore disease mechanisms and potential treatments in greater depth, ultimately facilitating the development of new and effective therapies.

Nitrase Therapeutics is a biopharmaceutical company developing therapies against a novel class of enzymes called nitrases, initially focusing on Parkinson’s disease. Its proprietary platform enables the identification and targeting of these enzymes to potentially slow or halt disease progression.

Casma Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing innovative therapeutic strategies centered on the natural cellular process of autophagy. Founded in 2017, the company aims to enhance autophagy to improve the clearance of unwanted proteins, organelles, and pathogens, thereby addressing significant medical challenges. Casma Therapeutics is advancing preclinical programs targeting various conditions, including muscle disorders, liver disease, inflammatory disorders, and neurodegenerative diseases. By harnessing and manipulating the autophagy system, the company seeks to arrest or reverse disease progression, ultimately enabling physicians to meet unmet medical needs and provide effective treatments for patients with serious health issues.

Aprinoia Therapeutics Inc. is a clinical-stage biotechnology company focused on advancing brain health through innovative diagnostic tools and therapies for neurodegenerative diseases. Founded in 2015 and headquartered in Taipei, Taiwan, with additional locations in China and Japan, Aprinoia develops imaging-based diagnostics, including 18F-PM-PBB3, a tau positron-emission tomography (PET) tracer that aids in the diagnosis of tauopathies. The company also manufactures an alpha-synuclein PET imaging tracer. By targeting protein aggregates associated with conditions like Alzheimer's and Parkinson's diseases, Aprinoia aims to enhance precision medicine in neuroscience and improve patient outcomes. The company's commitment to addressing the complexities of neurodegenerative diseases positions it as a leader in the development of first-in-class and best-in-class diagnostic and therapeutic solutions.

Inflazome Ltd. is a biotechnology company based in Dublin, Ireland, established in 2016. The company specializes in developing orally available drugs aimed at addressing unmet clinical needs in inflammatory diseases by targeting inflammasomes, which are critical in the inflammatory process. Inflazome's innovative therapies are designed to block inflammasome signals, thereby addressing the root causes of inflammation. The company's portfolio includes treatments for a range of conditions, such as neurological disorders like Alzheimer's and Parkinson's, systemic inflammatory diseases, and certain orphan diseases. As of September 2020, Inflazome operates as a subsidiary of Roche Holding AG, further enhancing its capacity to deliver targeted therapies in the field of inflammatory diseases.

Amydis is a privately-held pharmaceutical company dedicated to developing innovative diagnostic tools for detecting diseases linked to amyloid protein deposits. Its core technology involves novel compounds that fluoresce upon binding to amyloid proteins, enabling non-invasive diagnosis. Amydis' primary focus is on early-stage Alzheimer's disease detection, with other potential applications including Parkinson's disease, Creutzfeldt-Jakob disease, and various forms of amyloidosis. The company aims to provide faster, more accessible, and affordable diagnostic solutions compared to existing methods, contributing to better healthcare decisions for patients and their families.

Alkahest, Inc. is a clinical-stage biopharmaceutical company based in San Carlos, California, founded in 2014. The company specializes in developing therapies derived from blood to address neurological diseases, particularly those associated with aging, such as Alzheimer’s disease and Parkinson’s disease. Alkahest's innovative research has shown that factors in the blood plasma of younger organisms can reverse cognitive deficits associated with aging and neurodegenerative diseases in animal models. The company aims to enhance health and vitality by creating transformative treatments that mitigate the negative effects of aging. Alkahest operates as a subsidiary of Grifols, a global healthcare company known for its plasma therapies.

OccamzRazor develops an AI-powered platform for neuroscience drug discovery and development. It combines machine learning with first-in-class biological techniques to integrate unstructured biomedical text with structured data such as genomics, proteomics and phenomics, generating stronger hypotheses for target identification and drug repurposing. The company's technology analyzes diverse data sources to construct a comprehensive knowledge graph that captures all known information about Parkinson's disease, enabling clinicians and researchers to derive downstream therapeutic insights and to guide strategic drug development.

Neuropore Therapies is a pharmaceutical company located in San Diego, CA committed to the discovery and development of disease-modifying treatments for neurodegenerative disorders, including Parkinson’s disease and Alzheimer’s disease. They are located on Road to the Cure in San Diego, CA.Their approach is based on the fundamental concept that the pathological accumulation of misfolded and aggregated neurotoxic proteins is the underlying basis of these disorders. Their therapeutic candidates directly target these proteins and restore cellular autophagy mechanisms to degrade and dispose of these neurotoxic proteins.

MISSION Therapeutics is a biotechnology company specializing in developing drugs that target the cellular process of deubiquitylation for the treatment of cancer and other diseases. Their focus is on developing small molecule drugs that selectively inhibit specific deubiquitylating enzymes (DUBs), which play crucial roles in regulating protein degradation and cellular processes. These drugs aim to intervene in disease mechanisms where DUB dysregulation is implicated, offering potential therapeutic benefits.

Inhibikase Therapeutics is a clinical-stage pharmaceutical company focused on developing therapeutics for Parkinson's Disease and related disorders affecting the brain and other parts of the body. The company's lead product candidate, IkT-148009, is a c-Abl protein kinase inhibitor aimed at treating Parkinson's Disease, dysphagia, and neurogenic constipation. Additionally, Inhibikase is advancing IkT-001Pro, a prodrug of the anti-cancer agent Imatinib, which is designed to reduce gastrointestinal side effects. Other notable candidates include IkT-01427, which targets the virus responsible for progressive multifocal leukoencephalopathy, and the IkT-148x series, intended for Dementia with Lewy Body and Multiple System Atrophy. Founded in 2008 and headquartered in Atlanta, Georgia, Inhibikase has also developed a small molecule platform that targets both bacterial and viral infectious diseases through a unified mechanism, aiming to create effective multi-pathogen anti-infectives while minimizing resistance development.

Addex Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing oral small-molecule drugs that act as allosteric modulators of central nervous system targets, especially G-protein coupled receptors. Based in Geneva, Switzerland, the company aims to address CNS disorders with a platform that may offer advantages over conventional orthosteric therapies. Its lead programs include Dipraglurant for Parkinson's disease levodopa-induced dyskinesia and dystonia, ADX71149 for epilepsy and other CNS conditions, and a GABAB positive allosteric modulator for addiction. It collaborates with Janssen Pharmaceuticals to develop mGluR2 PAM compounds. Founded in 2002, Addex operates in Switzerland and Europe, pursuing discovery, development, and potential commercialization of small-molecule therapeutics for CNS disorders.

Neuropore Therapies is a pharmaceutical company located in San Diego, CA committed to the discovery and development of disease-modifying treatments for neurodegenerative disorders, including Parkinson’s disease and Alzheimer’s disease. They are located on Road to the Cure in San Diego, CA.Their approach is based on the fundamental concept that the pathological accumulation of misfolded and aggregated neurotoxic proteins is the underlying basis of these disorders. Their therapeutic candidates directly target these proteins and restore cellular autophagy mechanisms to degrade and dispose of these neurotoxic proteins.

Asceneuron is a biotechnology company dedicated to discovering and developing therapeutics for neurodegenerative disorders with high unmet medical needs. It focuses on orphan tauopathies, Alzheimer's disease, and Parkinson's disease.

Saniona is a pharmaceutical company focused on discovering and developing medicines that modulate ion channels to treat central nervous system disorders, autoimmune diseases, metabolic diseases, and pain. It operates a technology platform that enables investigation of ion channel targets, including GABAA receptors, nicotinic acetylcholine receptors, and potassium channels, to create selective modulators. Its product pipeline includes Tesomet, SAN711, SAN903, and SAN2219; Tesomet has advanced to mid-stage trials for rare eating disorders, SAN711 completed a Phase 1 trial for neuropathic pain, SAN903 is positioned to enter Phase 1 trials for inflammatory and fibrotic disorders, and SAN2219 is in development. Saniona operates in the United States, Sweden, Germany, Denmark, and the United Kingdom.

nLife Therapeutics S.L. is a biopharmaceutical company based in Granada, Spain, with an additional office in Barcelona. Founded in 2009, the company focuses on developing innovative treatments for central nervous system (CNS) and neuromuscular disorders through the use of cell-specific oligonucleotides. nLife Therapeutics specializes in first-in-class disease-modifying therapies, including a treatment that selectively silences alpha-synuclein in monoaminergic neurons to halt toxic accumulation associated with Parkinson's disease. Additionally, the company targets Huntington’s Disease by reducing levels of altered Htt in striatal and cortical neurons to impede disease progression. Their technology employs conjugated nucleic acids delivered to selected neurons via a single intra-nasal application, positioning nLife Therapeutics at the forefront of next-generation targeted nucleic acid products.

Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, focused on the discovery and early development of therapeutic drugs targeting G protein-coupled receptors (GPCRs), which are key drug targets in various diseases. Founded in 2001, the company specializes in developing small molecules for the treatment of central nervous system (CNS) disorders and cancer. It employs its proprietary technology platform, DTect-All, which enables the identification of orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs) that are challenging to discover using conventional methods. In addition, Domain Therapeutics offers BioSens-All, a platform to explore the signaling complexities associated with GPCR activation, enhancing its ability to address difficult targets, such as orphan and peptidic GPCRs.

Motus Therapeutics is a biotechnology company located in Boston, Massachusetts, focused on developing peptide therapeutics to address unmet needs in metabolic diseases. The company specializes in treatments for gastrointestinal disorders, with its lead product candidate, relamorelin, acting as a ghrelin agonist. Relamorelin is specifically designed for the treatment of diabetic gastroparesis, a gastrointestinal complication associated with diabetes, as well as other gastrointestinal functional disorders. Through its innovative approach, Motus Therapeutics aims to improve the quality of life for patients suffering from these conditions.

ZelosDx is a company focused on developing neurodiagnostic technologies, specifically blood testing products aimed at advancing research in brain health and disease. It offers proprietary technology that allows research collaborators to license and adapt blood testing kits and automated laboratory equipment. Additionally, the company provides pharmaceutical partners with biomarker technology essential for drug discovery tools. By delivering critical data for diagnosis, monitoring, and assessing therapeutic responses, ZelosDx supports researchers and pharmaceutical companies in making significant breakthroughs in understanding and treating brain-related conditions.

Addex Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing oral small-molecule drugs that act as allosteric modulators of central nervous system targets, especially G-protein coupled receptors. Based in Geneva, Switzerland, the company aims to address CNS disorders with a platform that may offer advantages over conventional orthosteric therapies. Its lead programs include Dipraglurant for Parkinson's disease levodopa-induced dyskinesia and dystonia, ADX71149 for epilepsy and other CNS conditions, and a GABAB positive allosteric modulator for addiction. It collaborates with Janssen Pharmaceuticals to develop mGluR2 PAM compounds. Founded in 2002, Addex operates in Switzerland and Europe, pursuing discovery, development, and potential commercialization of small-molecule therapeutics for CNS disorders.

Envoy Therapeutics is a biotechnology company focused on drug discovery, aiming to develop new therapeutics with enhanced efficacy and reduced side effects compared to existing treatments. Utilizing its proprietary bacTRAP® technology, the company can identify proteins produced by specific cell types in vivo, eliminating the need for cell isolation. This innovative approach is particularly beneficial in complex tissues such as the brain, where numerous cell types coexist. By enabling the precise modulation of cell activity through the identification of unique protein expressions, Envoy Therapeutics is positioning itself at the forefront of advancements in targeted drug development.

Trevena, Inc., founded in 2007 and headquartered in Chesterbrook, Pennsylvania, is a biopharmaceutical company dedicated to the development of innovative medicines for central nervous system (CNS) disorders. The company specializes in creating G protein-coupled receptor (GPCR) biased ligands, which aim to improve upon existing therapies by enhancing efficacy and reducing adverse effects. Trevena's pipeline includes several product candidates: Oliceridine injection, a mu-opioid receptor ligand completed Phase III trials for acute pain management; TRV250, a delta-opioid receptor agonist in Phase I study for migraine treatment; TRV734, a small molecule MOR ligand in Phase I study for acute and chronic pain; TRV027, currently in phase 2 clinical testing for the treatment of acute heart failure; and TRV045, an S1P modulator for managing chronic pain. Trevena has also collaborated with Imperial College London to evaluate Trv027 in Covid-19 patients.

Sapiens Steering Brain Stimulation GmbH is a medical device company focused on advancing deep brain stimulation (DBS) therapy. Founded in 2011 as a spin-out of Royal Philips Electronics, Sapiens operates from offices in Eindhoven, the Netherlands, and Munich, Germany. The company is dedicated to developing a high-resolution, MRI-compatible DBS system designed to enhance patient comfort and improve therapeutic outcomes, particularly for individuals with Parkinson's disease. Sapiens’ innovative approach includes a unique steering brain stimulation system and image-guided programming, both of which are based on patented technologies.

Amicus Therapeutics is a biotechnology company focused on discovering, developing, and delivering therapies for rare and orphan diseases. It specializes in oral pharmacological chaperones—small molecules that bind, stabilize, and enhance activity of misfolded enzymes—to treat lysosomal storage disorders such as Fabry and Pompe disease, and it explores combination approaches with enzyme replacement therapy. The company maintains a growing pipeline targeting additional lysosomal diseases, including Gaucher, and collaborates with academic and clinical partners to advance its programs. Amicus was founded in 2002 and is headquartered in Cranbury, New Jersey.

Ceregene is a private biotechnology company based in San Diego, specializing in treatments for major neurodegenerative disorders through the delivery of nervous system growth factors. The company's clinical programs include CERE-110, an AAV2-based vector designed to express nerve growth factor, which is set to enter Phase 2 trials for Alzheimer's disease. Additionally, Ceregene is advancing CERE-120, which has completed Phase 2 trials for Parkinson's disease and is currently under evaluation for further development. The company is also developing CERE-135 and CERE-140, both of which are in preclinical stages, targeting amyotrophic lateral sclerosis (ALS) and various ocular diseases, respectively.

Omeros discovers, develops, and commercializes small-molecule and protein therapeutics for large-market and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system, immunologic disorders, cancers, and addictive/compulsive disorders.

Umecrine Cognition is a biopharmaceutical company established in 2006, focusing on developing drugs to treat neurological disorders in the central nervous system (CNS) caused by endogenous CNS-active steroids, specifically GABA-steroids. The company's primary objective is to discover and commercialize novel therapeutics for treating Hepatic Encephalopathy, a cognitive disorder affecting patients with liver disease. Umecrine Cognition operates as a lean organization within a competent network, collaborating with Karolinska Development since its inception as a subsidiary of Umecrine AB.

Verily is an Alphabet health technology company focused on research, care, and health financing to deliver on the promise of precision health and help people live healthier lives. We are uniquely positioned at the intersection of technology, data science, and healthcare to create tools to accelerate evidence generation, products to enable more personalized care, and approaches to make costs more predictable. For more information about Verily please visit verily.com. The company was founded in 2015 and is based in San Francisco, California, United States.

Hillhurst Biopharmaceuticals specializes in developing innovative, liquid therapeutic gases for treating sickle cell disease. Their core technology enables the oral delivery of low-dose carbon monoxide, targeting the protective heme oxygenase system to reduce inflammation, prevent cell death, and halt hemoglobin polymerization. This approach addresses challenges associated with traditional inhaled gas therapies, such as caregiver exposure and imprecise dosing, ensuring accurate and safe administration.

Montara Therapeutics is a biotechnology company specializing in brain-specific pharmacology. It leverages human genetics and machine learning to identify and validate drug targets, aiming to enhance the safety and efficacy of treatments for neurological diseases.